Phalanx Biotech Group Co., Ltd of Hsinchu at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option
Manufacturers Trader Service

Phalanx Biotech Group Co., Ltd

6f, No.6, Technology Rd 5, Hsinchu Science Park, 30078 Hsinchu
Taiwan
Telephone +886 3 5781168
Fax +886 3 5785099
info@phalanxbiotech.com

This company is co-exhibitor of
Kaigo Co., Ltd.

Hall map

MEDICA 2019 hall map (Hall 17): stand D46

Fairground map

MEDICA 2019 fairground map: Hall 17

Contact

Jack Huang

Marketing Assistant Vice President

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.01  DNA testing

Our products

Product category: DNA testing

【Genetic Testing】 Chromosomal Microarray| Liver Cancer ctDNA Methylation|SNP genotyping

  • Reproductive Medicine  - Phalanx Biotech self-developed the product of chromosomal microarray-"CytoOneArray", which can identify chromosomal aneuploidy and other large changes in the structure of chromosomes in prenatal and postnatal testing. CytoOneArray is capable of detecting more than +400 diseases per test, effectively for Developmental Delay (DD) and Intellectual Disability (ID). It provides advanced genetic diagnostic tools for obstetricians and pediatricians.
  • Liver Cancer ctDNA Methylation Test - A breakthrough genetic testing development by leveraging ctDNA methylation markers for early liver cancer detection and screening.
  • Population Medicine - Risk and predisposition assessment for obesity, 13 chronic diseases & 17 cancers. Additionally providing custom arrays for SNP genotyping and custom-designed services for consumer genetic testing.

More Less

Company news

Date

Topic

Download

Sep 27, 2019

《Discovery Channel》Feature Story Report - “Health Heroes” (Phalanx BioTech)

Phalanx is the Global Four and the Only High Density Biochip Provider in Asia.
PS. Please refer to the link for the news video clip

More Less

Sep 6, 2019

《Yahoo News》A boy with cataract has been diagnosed with Lowe Syndrome by postnatal genetic testing!

Phalanx Group, a key player in prenatal and postnatal genetic testing, such as Developmental Delays (DD) & Intellectual Disorders (ID), has been supporting pediatrician to discover rare childhood diseases from an early stage.

PS. Please refer to the link for the news story

More Less

About us

Company details

Phalanx Biotech, headquartered in Taiwan for 17 years, is dedicated to the development of genetic detection platform, incorporated with Microarrays, Next Generation Sequencing (NGS) and Big Data analysis for health informatics, positioning as the only microarray developer in Asia. The core services of Phalanx Biotech lie upon five areas within Reproductive Medicine (prenatal/postnatal testing), Population Medicine, Medical Oncology, Liver Cancer ctDNA Methylation Test, and scientific research services.

  • Reproductive Medicine - Phalanx Biotech self-developed the product of chromosomal microarray-"CytoOneArray", which can identify chromosomal aneuploidy and other large changes in the structure of chromosomes in prenatal and postnatal testing. CytoOneArray is capable of detecting more than +400 diseases per test, effectively for Developmental Delay (DD) and Intellectual Disability (ID). It provides advanced genetic diagnostic tools for obstetricians and pediatricians.
  • Liver Cancer ctDNA Methylation Test - A breakthrough genetic testing development by leveraging ctDNA methylation markers for early liver cancer detection and screening.
  • Population Medicine - Risk and predisposition assessment for obesity, 13 chronic diseases & 17 cancers. Additionally providing custom arrays for SNP genotyping and custom-designed services for consumer genetic testing.
  • Medical Oncology - Provides genetic tests for new generation cancer medications for the treatment tailored to each patient.

More Less

Company data

Area of business

Diagnostics